| [Fire Fighting] Extinguish using Water spray. Carbon dioxide, dry chemical powder, or appropriate foam. Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. | |
| [Ingestion] Benzodiazepines or droperidol and minimization of sensory stimuli may reduce the incidence of psychotomimetic effects of ketamine. Administer oxygen and manage airway as clinically indicated. | |
| [Inhalation] See ingestion. | |
| [Skin] Remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician may need to examine the area if irritation or pain persists. | |
| [Eyes] Irrigate eye for at least 20 minutes with water or saline. If irritation persists, seek medical attention. | |
| [Storage] Keep tightly closed. Store at 2-8 C | |
| [Inhalation] Respiratory depression, apnea, and respiratory arrest may occur. Ketamine may produce bronchodilation and increased salivary and tracheobronchial secretions. | |
| [Skin] May be harmful if absorbed through the skin. | |
| [Eyes] Temporary loss of vision or blurred vision may be noted. | |
| [Ingestion] Nausea and vomiting have been reported. | |
| [Hazards] Emits toxic fumes under fire conditions. | |
| [EC Risk Phrase] 22 36/37/38 40 | |
| [EC Safety Phrase] 26 36 | |
| [Personal Protection] Compatible chemical-resistant gloves. Chemical safety goggles. | |
| [Respirators] Government approved respirator. | |
| [Exposure Effects] Sedation and respiratory depression have been reported after overdose in medical settings. Patients usually awaken within a few hours, although sedation lasting 24 hours has been described. Ketamine has become a drug of abuse. Common effects include tachycardia, altered mental status, anxiety, palpitations, slurred speech hallucinations, nystagmus, mydriasis, mild hypertension and chest pain. Confusion, vomiting and memory loss are less common. Rarely seizures, polyneuropathy, or respiratory arrest may occur. Death is rare following ketamine abuse or overdose. | |
| [Appearance] Colorless to white crystals. | |
| [Solubility in water] 0.2 g/mL (20 C) | |
| [Melting Point] 262 - 263 | |
| [Usage] Medication. Selective nmda glutamate receptor antagonist; veterinary anesthetic. | |
| [Product Name] Ketamine hydrochloride | |
| [Synonyms] (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride Calipsol CI 581 Kalipsol Ketaset Vetalar | |
| [CAS] "CASEN_1867-66-9.htm">1867-66-9 | |
| [Formula] C13H16ClNO.ClH | |
| [Molecular Weight] 274.20999999999998 | |
| [EINECS] 217-484-6 | |
| [RTECS] GW1400000 | |
| [RTECS Class] Drug; Mutagen; Reproductive Effector; Human Data | |
| [Beilstein/Gmelin] 5318526 | |
| [Beilstein Reference] 6-14 | |
| [Small spills/leaks] Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete. | |
| [Incompatibilities] Oxidizing agents. | |
| [Stability] Stable at normal temperatures and pressures. | |
| [Decomposition] When heated to decomposition, the material emits fumes of HCl and NOx. |
Print